HIMS Stock Recent News
HIMS LATEST HEADLINES
Small-cap healthcare stocks might be the next stock market goldmine, but many investors are overlooking the sector's potential. Small-cap healthcare stocks tend to be nimbler and more innovative than their blue-chip counterparts (with some exceptions), meaning they're better equipped to navigate tricky market conditions and changing industry trends.
Hims & Hers aims to destigmatize certain aspects of healthcare while making access to care more convenient. The company's massive growth rate and burgeoning profitability could reward investors over the coming years.
Hims & Hers Health, Inc. (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Analysts believe Hims & Hers Health will lose money in 2024. But comments from the CEO signal this could be wrong.
Hims & Hers Health: Faultless, Ready To Go Higher
Hims & Hers Health has reported strong quarterly results and improved profits, leading to a stock snapback. The company is moving into AI-based medical services and weight loss management to address soaring costs. The stock is incredibly cheap trading at less than 2x sales while forecast to top 20% growth for years ahead.
Hims & Hers Health raised its guidance once again when it reported its Q3 results. The company saw significant growth in subscribers, particularly in the mental health and women's health sectors. HIMS is one of the cheapest growth stocks around.
SentinelOne keeps delivering cutting-edge tech and strong growth. Roku is an entrenched streaming leader with future growth ahead.
Hims & Hers Health is a telemedicine company specializing in a variety of treatments. The company's unique subscription model has helped propel strong top-line growth and margin expansion.
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Novo Nordisk A/S NYSE: NVO Semaglutide drug Ozempic to go mainstream and viral as countless consumers try the medication that was originally approved for type 2 diabetes patients.